Can a brain scan reveal Alzheimer's secrets?
NCT ID NCT07127510
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with Alzheimer's disease have lower levels of a natural chemical called NAD in their brains compared to healthy older adults. Researchers will use a special MRI scan to measure NAD in 20 volunteers aged 65 to 80. Participants will have two scans, eight months apart, to track changes over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Primary care clinic, community.
- Ages
-
65 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory. * Age 65 to 80 included. * People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test. Exclusion Criteria: * Under the age of 65 or over the age of 80. * Advanced dementia such that the person would require sedation for undergoing an MRI scan. * Receiving anti-amyloid intravenous treatments Leqembi or Kinsula. * Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part). * Having a history of seizures. * Working at night. * Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer). * People with no AD: MoCA test result lower than 26.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
FAU Clinical Research Unit
RECRUITINGBoca Raton, Florida, 33431, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your phone might notice Alzheimer's decline before you do
- Gut bacteria may hold clues to memory decline
- Could a breath test reveal Parkinson's risk?
- Could a common supplement slow Alzheimer's decline?
- Could a simple beat help Alzheimer's patients walk better?
- Lifestyle makeover could slash Alzheimer's risk in genetically vulnerable seniors